Tumor Suppressor VDUP1 Increases p27kip1 Stability by Inhibiting JAB1
Authors:
Open Access
- 1 June 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (11) , 4485-4489
Abstract
Heteroaromatic quinols 4-(benzothiazol-2-yl)-4-hydroxycyclohexa-2,5-dienone (1) and 4-(1-benzenesulfonyl-1H-indol-2-yl)-4-hydroxycyclohexa-2,5-dienone (2) exhibit potent and selective antitumor activity against colon, renal, and breast carcinoma cell lines in vitro (GI50 < 500 nmol/L). In vivo growth inhibition of renal, colon, and breast xenografts has been observed. Profound G2-M cell cycle block accompanied down-regulation of cdk1 gene transcription was corroborated by decreased CDK1 protein expression following treatment of HCT 116 cells with growth inhibitory concentrations of 1 or 2. The chemical structure of the quinol pharmacophore 4-(hydroxycyclohexa-2,5-dienone) suggested that these novel agents would readily react with nucleophiles in a double Michael (β-carbon) addition. Indeed, COMPARE analysis within the National Cancer Institute database revealed a number of chemically related quinone derivatives that could potentially react with sulfur nucleophiles in a similar manner and suggested that thioredoxin/thioredoxin reductase signal transduction could be a putative target. Molecular modeling predicted covalent irreversible binding between quinol analogues and cysteine residues 32 and 35 of thioredoxin, thereby inhibiting enzyme activity. Binding has been confirmed, via mass spectrometry, between reduced human thioredoxin and 1. Microarray analyses of untreated HCT 116 cells and those exposed to either 1 (1 μmol/L) or 2 (500 nmol/L and 1 μmol/L) determined that of ≥10,000 cancer-related genes, expression of thioredoxin reductase was up-regulated >3-fold. Furthermore, quinols 1 and 2 inhibited insulin reduction, catalyzed by thioredoxin/thioredoxin reductase signaling in a dose-dependent manner (IC50 < 6 μmol/L). Results are consistent with a mechanism of action of novel antitumor quinols involving inhibition of the small redox protein thioredoxin.Keywords
This publication has 21 references indexed in Scilit:
- VDUP1 Is Required for the Development of Natural Killer CellsImmunity, 2005
- Skp2-dependent degradation of p27kip1 is essential for cell cycle progressionGenes & Development, 2004
- Vitamin D3 receptor/Sp1 complex is required for the induction of p27Kip1 expression by vitamin D3Oncogene, 2004
- Distinct roles for p53, p27Kip1, and p21Cip1 during tumor developmentOncogene, 2003
- Vitamin D Inhibits G1 to S Progression in LNCaP Prostate Cancer Cells through p27Kip1 Stabilization and Cdk2 Mislocalization to the CytoplasmJournal of Biological Chemistry, 2003
- VDUP1 upregulated by TGF-β1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progressionOncogene, 2003
- Tumor suppression by Ink4a–Arf: progress and puzzlesCurrent Opinion in Genetics & Development, 2003
- Skp2 is oncogenic and overexpressed in human cancersProceedings of the National Academy of Sciences, 2001
- p27kip1: A Multifunctional Cyclin-Dependent Kinase Inhibitor with Prognostic Significance in Human CancersThe American Journal of Pathology, 1999
- Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1994